Article
HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
Lung cancer (Amsterdam, Netherlands) - 1 Aug 2022
Cuppens Kristof, Baas Paul, Geerdens Ellen, Cruys Bert, Froyen Guy, Decoster Lynn, Thomeer Michiel, Maes Brigitte
Abstract excerpt
OBJECTIVES: Immune checkpoint inhibitors (ICIs) improved outcomes in non-small cell lung cancer (NSCLC) patients. We report the predictive utility of human leukocyte antigen class I (HLA-I) diversity and tumor mutational burden (TMB) by comprehensive next-generation sequencing. METHODS: 126 patients were included. TMB high was defined as ≥ 10 nonsynonymous mutations/Mb. Patients exhibit high HLA-I diversity if at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.